Figure 3.

Kaplan-Meier overall (a and c) and progression-free (b and d) survival curves for epithelial ovarian cancer patients with different clinical stages. Subgroup analyses according to clinical stage revealed that epithelial ovarian cancer patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group (a and b), but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups (c and d).